drugset / Trial / NCT01646255

Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients

NCT01646255

Phase 3 Completed 346 enrolled UCB Pharma UCB Trading (Shanghai) Co. Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this study was to demonstrate that Rotigotine transdermal patch is efficacious in Chinese subjects with advanced-stage Idiopathic Parkinson's Disease as an adjuvant therapy.

Timeline

Start
2012-07
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Rotigotine Unknown 4 mg Other
Subject Rotigotine Unknown 6 mg Other
Subject Rotigotine Unknown 8 mg Other
Subject Rotigotine Unknown 16 mg Other
Background Levodopa Small molecule

Indications